Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA and TARP peptide vaccine + Poly IC-LC
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This therapeutic vaccine is a combination immunotherapy developed by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of prostate cancer, specifically in patients with biochemical recurrence (elevated PSA) following initial definitive treatment. The vaccine formulation consists of two peptide antigens: Prostate-Specific Membrane Antigen (PSMA) and T-cell receptor gamma alternate reading frame protein (TARP), which are tumor-associated proteins frequently expressed in prostate cancer cells. These antigens are combined with Poly IC-LC (Hiltonol), a synthetic double-stranded RNA that acts as a potent immunological adjuvant. Poly IC-LC stimulates the innate immune system by activating Toll-like receptor 3 (TLR3) and MDA5, which in turn enhances the maturation of dendritic cells and the induction of a robust T-cell mediated immune response against the targeted prostate cancer antigens. The vaccine is designed to train the immune system to recognize and eliminate residual or recurrent prostate cancer cells.
- Other names
- PSMA/TARP/Poly IC-LC vaccineCombination PSMA and TARP Peptide With Poly IC-LC AdjuvantHiltonol-adjuvanted PSMA/TARP vaccine
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)PSMA (Prostate-specific membrane antigen)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)TARP (T cell receptor gamma alternate reading frame protein)
Beyond the preview
Go deeper on PSMA and TARP peptide vaccine + Poly IC-LC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA and TARP peptide vaccine + Poly IC-LC.